These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 33521063)

  • 1. Characteristics of the Electrocardiogram in Japanese Fabry Patients Under Long-Term Enzyme Replacement Therapy.
    Morimoto S; Nojiri A; Fukuro E; Anan I; Kawai M; Sakurai K; Kobayashi M; Kobayashi H; Ida H; Ohashi T; Shibata T; Yoshimura M; Eto Y; Hongo K
    Front Cardiovasc Med; 2020; 7():614129. PubMed ID: 33521063
    [No Abstract]   [Full Text] [Related]  

  • 2. Enzyme replacement therapy improves cardiac features and severity of Fabry disease.
    Motwani M; Banypersad S; Woolfson P; Waldek S
    Mol Genet Metab; 2012 Sep; 107(1-2):197-202. PubMed ID: 22704481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of electrocardiogram in the differentiation of hypertensive heart disease, hypertrophic cardiomyopathy, aortic stenosis, amyloidosis, and Fabry disease.
    Namdar M; Steffel J; Jetzer S; Schmied C; Hürlimann D; Camici GG; Bayrak F; Ricciardi D; Rao JY; de Asmundis C; Chierchia GB; Sarkozy A; Lüscher TF; Jenni R; Duru F; Brugada P
    Am J Cardiol; 2012 Feb; 109(4):587-93. PubMed ID: 22105784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of left ventricular hypertrophy on QT prolongation and associated mortality.
    Haugaa KH; Bos JM; Borkenhagen EJ; Tarrell RF; Morlan BW; Caraballo PJ; Ackerman MJ
    Heart Rhythm; 2014 Nov; 11(11):1957-65. PubMed ID: 24956189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The beneficial effects of long-term enzyme replacement therapy on cardiac involvement in Japanese Fabry patients.
    Hongo K; Ito K; Date T; Anan I; Inoue Y; Morimoto S; Ogawa K; Kawai M; Kobayashi H; Kobayashi M; Ida H; Ohashi T; Taniguchi I; Yoshimura M; Eto Y
    Mol Genet Metab; 2018 Jun; 124(2):143-151. PubMed ID: 29747997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of changes in left ventricular anatomy and conduction velocity on the QRS voltage and morphology in left ventricular hypertrophy: a model study.
    Bacharova L; Szathmary V; Kovalcik M; Mateasik A
    J Electrocardiol; 2010; 43(3):200-8. PubMed ID: 19709670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of Electrocardiography to Distinguish Fabry Disease from Sarcomeric Hypertrophic Cardiomyopathy.
    Antezana-Chavez E; Cianciulli TF; Hadid CL; Toro DD; Celano L; Saccheri MC; Baez KG; Lopez CA; Labadet CD; Gagliardi JA
    Am J Cardiol; 2022 Sep; 178():131-136. PubMed ID: 35810008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electrocardiographic Characteristics and Their Correlation with Echocardiographic Alterations in Fabry Disease.
    Zada M; Lo Q; Trivedi SJ; Harapoz M; Boyd AC; Devine K; Sadick N; Tchan MC; Thomas L
    J Cardiovasc Dev Dis; 2022 Jan; 9(1):. PubMed ID: 35050221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fabry Disease and the Effectiveness of Enzyme Replacement Therapy (ERT) in Left Ventricular Hypertrophy (LVH) Improvement: A Review and Meta-Analysis.
    Lee CL; Lin SP; Niu DM; Lin HY
    Int J Med Sci; 2022; 19(1):126-131. PubMed ID: 34975306
    [No Abstract]   [Full Text] [Related]  

  • 10. The relationship between electrocardiographic left ventricular hypertrophy criteria and echocardiographic mass in patients undergoing transcatheter aortic valve replacement.
    Sjöberg S; Sundh F; Schlegel T; Maynard C; Rück A; Wagner G; Ugander M
    J Electrocardiol; 2015; 48(4):630-6. PubMed ID: 25865909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secondary and primary repolarization changes in left ventricular hypertrophy: a model study.
    Bacharova L; Szathmary V; Mateasik A
    J Electrocardiol; 2010; 43(6):624-33. PubMed ID: 20719330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serial evaluation of electrocardiographic left ventricular hypertrophy for prediction of risk in hypertensive patients.
    Okin PM
    J Electrocardiol; 2009; 42(6):584-8. PubMed ID: 19631946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time-voltage QRS area of the 12-lead electrocardiogram: detection of left ventricular hypertrophy.
    Okin PM; Roman MJ; Devereux RB; Pickering TG; Borer JS; Kligfield P
    Hypertension; 1998 Apr; 31(4):937-42. PubMed ID: 9535418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Findings relevant to the QRS wave in the resting electrocardiogram are associated with circulating concentrations of high-sensitivity cardiac troponin I in the general population.
    Sugiura T; Dohi Y; Takase H; Fujii S; Ohte N
    J Am Soc Hypertens; 2018 Aug; 12(8):614-620. PubMed ID: 29886153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electrocardiogram analysis in Anderson-Fabry disease: a valuable tool for progressive phenotypic expression tracking.
    Parisi V; Baldassarre R; Ferrara V; Ditaranto R; Barlocco F; Lillo R; Re F; Marchi G; Chiti C; Di Nicola F; Catalano C; Barile L; Schiavo MA; Ponziani A; Saturi G; Caponetti AG; Berardini A; Graziosi M; Pasquale F; Salamon I; Ferracin M; Nardi E; Capelli I; Girelli D; Gimeno Blanes JR; Biffi M; Galiè N; Olivotto I; Graziani F; Biagini E
    Front Cardiovasc Med; 2023; 10():1184361. PubMed ID: 37416917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electrocardiographic patterns and long-term training-induced time changes in 2484 elite football players.
    Huttin O; Selton-Suty C; Venner C; Vilain JB; Rochecongar P; Aliot E
    Arch Cardiovasc Dis; 2018 May; 111(5):380-388. PubMed ID: 29275944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Echocardiographic and clinical findings in patients with Fabry disease during long-term enzyme replacement therapy: a nationwide Danish cohort study.
    Madsen CV; Bundgaard H; Rasmussen ÅK; Sørensen SS; Petersen JH; Køber L; Feldt-Rasmussen U; Petri H
    Scand Cardiovasc J; 2017 Aug; 51(4):207-216. PubMed ID: 28545342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progression of electrocardiogram changes in an untreated fabry disease: a case report.
    Mattig I; Canaan-Kühl S; Tillmanns C; Knebel F
    Eur Heart J Case Rep; 2021 Feb; 5(2):ytab045. PubMed ID: 33738419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Left atrial enlargement and reduced atrial compliance occurs early in Fabry cardiomyopathy.
    Boyd AC; Lo Q; Devine K; Tchan MC; Sillence DO; Sadick N; Richards DA; Thomas L
    J Am Soc Echocardiogr; 2013 Dec; 26(12):1415-23. PubMed ID: 24094560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Limited effects of long-term enzyme replacement therapy on the cardiac conduction system in Fabry disease.
    Kaneda T; Takeda M; Suematsu T; Yamamoto R; Takata M; Higashikata T; Ino H; Tsujibata A; Hayashi K; Fujino N; Kawashiri MA
    J Cardiol Cases; 2018 May; 17(5):178-181. PubMed ID: 30279886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.